Display options
Cite
Khosla S, Patel VM, Hay ID, et al. Loss of heterozygosity suggests multiple genetic alterations in pheochromocytomas and medullary thyroid carcinomas. J Clin Invest. 1991;87(5):1691-9doi: 10.1172/JCI115186.
Khosla, S., Patel, V. M., Hay, I. D., Schaid, D. J., Grant, C. S., van Heerden, J. A., & Thibodeau, S. N. (1991). Loss of heterozygosity suggests multiple genetic alterations in pheochromocytomas and medullary thyroid carcinomas. The Journal of clinical investigation, 87(5), 1691-9. https://doi.org/10.1172/JCI115186
Khosla, S, et al. "Loss of heterozygosity suggests multiple genetic alterations in pheochromocytomas and medullary thyroid carcinomas." The Journal of clinical investigation vol. 87,5 (1991): 1691-9. doi: https://doi.org/10.1172/JCI115186
Khosla S, Patel VM, Hay ID, Schaid DJ, Grant CS, van Heerden JA, Thibodeau SN. Loss of heterozygosity suggests multiple genetic alterations in pheochromocytomas and medullary thyroid carcinomas. J Clin Invest. 1991 May;87(5):1691-9. doi: 10.1172/JCI115186. PMID: 2022740; PMCID: PMC295269.
Copy Download .nbib Format: NLM
Share it on
Full text links
American Society for Clinical Investigation Free PMC Article

J Clin Invest. 1991 May;87(5):1691-9. doi: 10.1172/JCI115186.

Loss of heterozygosity suggests multiple genetic alterations in pheochromocytomas and medullary thyroid carcinomas.

The Journal of clinical investigation

S Khosla, V M Patel, I D Hay, D J Schaid, C S Grant, J A van Heerden, S N Thibodeau

Affiliations

  1. Department of Endocrinology and Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905.

PMID: 2022740 PMCID: PMC295269 DOI: 10.1172/JCI115186
Free PMC Article

Abstract

Loss of heterozygosity (LOH) at specific loci may help localize tumor suppressor genes involved in the formation of various familial and sporadic tumors. In addition, the genetic loci for a number of familial tumor syndromes have been mapped by linkage analysis. To explore the possible role of tumor suppressor genes in endocrine tumors, we tested 41 pheochromocytomas (34 sporadic and 7 familial) and 11 medullary thyroid cancers (MTC) (10 sporadic and 1 familial) for LOH near a variety of potentially important genetic loci: (a) the multiple endocrine neoplasia type 2A (MEN 2A) locus on chromosome 10; (b) the von Hippel-Lindau locus on 3p; and (c) the p53 and neurofibromatosis 1 loci on 17. We also examined chromosomes 1p and 22q because previous studies in a small number of pheochromocytomas and MTCs suggested LOH in these regions. Background rates for LOH were assessed using several "random" probes. Finally, we examined a number of clinical and histologic characteristics of these tumors for possible correlations with specific genetic alterations. LOH in the region of the MEN 2A locus was uncommon (0% for MTCs, 5% for pheochromocytomas). However, we found significant allelic losses in pheochromocytomas on chromosomes 1p (42%), 3p (16%), 17p (24%), and 22q (31%). We also noted a correlation between LOH on 1p and urinary excretion of metanephrine by these patients (P = 0.02). LOH on 1p, 3p, and 17p also appeared to be associated with increased tumor volume. Analysis of the smaller number of MTCs demonstrated allelic losses on chromosomes 1p and 22q. Our results suggest that tumor formation and/or progression in pheochromocytomas and MTCs involves multiple genes, analogous with the model proposed for colon carcinoma.

Similar articles

Show all 10 similar articles

Cited by

Williams MD, Ma J, Grubbs EG, Gagel RF, Bagheri-Yarmand R.
Am J Cancer Res. 2021 Jun 15;11(6):3227-3239. eCollection 2021.
PMID: 34249457

References

  1. J Mol Biol. 1975 Nov 5;98(3):503-17 - PubMed
  2. Science. 1990 Jul 13;249(4965):181-6 - PubMed
  3. Science. 1984 Jan 6;223(4631):71-4 - PubMed
  4. Cell. 1984 Jan;36(1):131-8 - PubMed
  5. Nucleic Acids Res. 1986 Feb 25;14(4):1923 - PubMed
  6. Proc Natl Acad Sci U S A. 1986 Mar;83(6):1772-6 - PubMed
  7. Am J Hum Genet. 1986 Apr;38(4):428-36 - PubMed
  8. Proc Natl Acad Sci U S A. 1986 Jul;83(14):5165-9 - PubMed
  9. Cytogenet Cell Genet. 1986;43(1-2):103-8 - PubMed
  10. Nature. 1987 Aug 6-12;328(6130):524-6 - PubMed
  11. Nature. 1987 Aug 6-12;328(6130):527-8 - PubMed
  12. Nature. 1987 Aug 6-12;328(6130):528-30 - PubMed
  13. Nature. 1987 Aug 13-19;328(6131):614-6 - PubMed
  14. Hum Genet. 1987 Oct;77(2):175-81 - PubMed
  15. Nature. 1987 Oct 15-21;329(6140):642-5 - PubMed
  16. Nucleic Acids Res. 1987 Dec 10;15(23):10073 - PubMed
  17. Nucleic Acids Res. 1988 Jan 11;16(1):374 - PubMed
  18. N Engl J Med. 1988 Mar 10;318(10):618-22 - PubMed
  19. Proc Natl Acad Sci U S A. 1988 Mar;85(5):1571-5 - PubMed
  20. Nature. 1988 Mar 3;332(6159):85-7 - PubMed
  21. Nature. 1988 Mar 17;332(6161):268-9 - PubMed
  22. Nucleic Acids Res. 1988 Feb 25;16(4):1645 - PubMed
  23. Genomics. 1987 Nov;1(3):257-63 - PubMed
  24. Mol Biol Med. 1988 Feb;5(1):15-22 - PubMed
  25. Nucleic Acids Res. 1988 Apr 25;16(8):3598 - PubMed
  26. N Engl J Med. 1988 Aug 4;319(5):278-83 - PubMed
  27. Nature. 1988 Sep 29;335(6189):400-2 - PubMed
  28. N Engl J Med. 1973 Aug 30;289(9):437-41 - PubMed
  29. J Cell Biol. 1974 Feb;60(2):523-7 - PubMed
  30. Jpn J Cancer Res. 1987 Sep;78(9):894-8 - PubMed
  31. Science. 1987 Dec 4;238(4832):1411-3 - PubMed
  32. N Engl J Med. 1988 Jan 21;318(3):151-7 - PubMed
  33. World J Surg. 1988 Aug;12(4):482-7 - PubMed
  34. Cytogenet Cell Genet. 1988;48(3):167-9 - PubMed
  35. Genomics. 1989 Apr;4(3):246-50 - PubMed
  36. N Engl J Med. 1989 May 25;320(21):1367-72 - PubMed
  37. Oncogene. 1989 Apr;4(4):451-5 - PubMed
  38. Proc Natl Acad Sci U S A. 1989 May;86(10):3753-7 - PubMed
  39. Am J Hum Genet. 1989 Jul;45(1):73-82 - PubMed
  40. Cancer Res. 1989 Aug 1;49(15):4114-9 - PubMed
  41. Nature. 1989 Dec 7;342(6250):705-8 - PubMed
  42. Cell. 1990 Jun 1;61(5):759-67 - PubMed
  43. Anticancer Res. 1990 Mar-Apr;10(2B):527-33 - PubMed
  44. Cell. 1990 Jul 13;62(1):193-201 - PubMed
  45. Am J Pathol. 1976 Apr;83(1):177-96 - PubMed

MeSH terms

Publication Types

LinkOut - more resources